Last C$146.75 CAD
Change Today +2.08 / 1.44%
Volume 1.1M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Frankfurt
As of 4:21 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Open
C$144.70
Previous Close
C$144.67
Day High
C$147.23
Day Low
C$144.67
52 Week High
02/27/14 - C$170.47
52 Week Low
10/31/13 - C$104.94
Market Cap
49.0B
Average Volume 10 Days
1.5M
EPS TTM
C$0.33
Shares Outstanding
333.6M
EX-Date
11/10/10
P/E TM
397.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (VRX)

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

17,200 Employees
Last Reported Date: 02/28/14
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.8M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Chief Legal Officer, Head of Corporate & Busi...
Total Annual Compensation: $750.0K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $511.1K
Consultant
Total Annual Compensation: $37.9K
Compensation as of Fiscal Year 2013.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International, Inc. Appoints Jeffrey W. Ubben as a Director of the Board, Effective on October 1, 2014

Valeant Pharmaceuticals International, Inc. announced that its Board of Directors has appointed Jeffrey W. Ubben, Founder, Chief Executive Officer, and the Chief Investment Officer of ValueAct Capital, as a director of the Board, effective as of October 1, 2014. Prior to founding ValueAct Capital in 2000, Mr. Ubben was a Managing Partner at Blum Capital Partners for more than five years.

Valeant Pharmaceuticals International, Inc. Revised Earnings Guidance for the Third Quarter of 2014; Provides Same Store Organic Growth Guidance for the Fourth Quarter of 2014

Valeant Pharmaceuticals International, Inc. revised earnings guidance for the third quarter of 2014. In the third quarter, the company expects results to be better than consensus on revenue, and better than the guidance it provided in second quarter earnings call for cash EPS, organic growth, restructuring charges and adjusted cash flow from operations. The company expects same store organic growth (unadjusted for generics) to exceed 15% with double-digit growth across almost all of major businesses and geographies and Bausch + Lomb continuing to deliver 10%+ same store organic growth (unadjusted). The company also expects continued strong double-digit same store organic growth in the fourth quarter of 2014.

Allergan Reportedly In Buyout Talks With Salix

Actavis plc (NYSE:ACT) is in buyout talks with Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), CNBC reported. Allergan Inc. (NYSE:AGN) has also been in talks with Salix as it tries to fend off an unwanted bid from Valeant Pharmaceuticals International, Inc. (TSX:VRX). Valeant said that such concerns were "completely unfounded." "In the third quarter, we expect our results to be better than consensus on revenue, and better than the guidance we provided in our second quarter earnings call for Cash EPS, organic growth, restructuring charges and adjusted cash flow from operations," Michael Pearson, Chief Executive Officer of Valeant said in a letter to Allergan's Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$146.75 CAD +2.08

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $241.28 USD -3.11
Astellas Pharma Inc ¥1,633 JPY -1.00
Mylan Inc/PA $45.49 USD -0.30
Shire PLC 5,340 GBp -25.00
Sun Pharmaceutical Industries Ltd 857.25 INR +21.45
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 8.2x
Price/Cash Flow 65.4x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.